Literature DB >> 28489692

TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION PATIENTS WITH VASCULAR ENDOTHELIAL GROWTH FACTOR INHIBITORS IN EVERYDAY PRACTICE: Identification of Health Care Constraints in Germany-The PONS Study.

Christoph Ehlken1,2, Thomas Wilke3, Ulrike Bauer-Steinhusen4, Hansjürgen T Agostini1, Zoran Hasanbasic4, Sabrina Müller3.   

Abstract

PURPOSE: The PONS study was conceived to analyze the extent of nonpersistence (NP) and nonadherence (NA) in the treatment of patients with neovascular age-related macular degeneration in everyday clinical practice in Germany. Further objectives were to identify factors that can affect NP and NA and to analyze clinical outcomes under everyday conditions.
METHODS: Nonpersistence (no contact with doctor for at least 3 months) and NA (no treatment or follow-up for at least 6 weeks) as well as clinical data were analyzed up to 24 months retrospectively and 12 months prospectively in 480 patients with neovascular age-related macular degeneration in 23 treatment centers. Patients were interviewed for factors possibly affecting NP and NA.
RESULTS: One third of patients fulfilled criteria of NA in the first 3 months and two thirds after 6 months. The NP was 18.8% after 12 months. Treatment exclusively at one center, a higher number of patients with neovascular age-related macular degeneration at the treating center, and fixed appointments were associated with a lower risk for NP. An initial gain in visual acuity after upload was not preserved after 12 months (mean change -0.5 Early Treatment Diabetic Retinopathy Study letters). Whereas visual acuity declined by 7.5 Early Treatment Diabetic Retinopathy Study letters in patients with good baseline visual acuity >20/40, visual acuity improved by 8.5 letters in patients with baseline visual acuity of ≤20/200. Only 7.5% of patients underwent an optical coherence tomography scan after 3 upload injections, and only 2.0 optical coherence tomographies were performed in the first 12 months.
CONCLUSION: The NP and NA were high in our study population and are likely to have contributed to a suboptimal clinical outcome compared with randomized clinical trials. Shortcomings in the management of patients with neovascular age-related macular degeneration, including restrictions in the timely and adequate follow-up (including optical coherence tomography) and retreatment, appear to be constraining factors in Germany.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 28489692     DOI: 10.1097/IAE.0000000000001681

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  8 in total

1.  Subjective evaluation of visual acuity is not reliable to detect disease activity in different exudative maculopathies.

Authors:  Marie-Christine Bruender; Nicola Benjamin; Hansjuergen Thomas Agostini; Andreas Stahl; Christoph Ehlken
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2018-06-01       Impact factor: 3.117

Review 2.  [IVOM quality assurance in Westfalen-Lippe : Structure of quality assurance and results of the pilot study Q-VERA].

Authors:  J Stasch-Bouws; S M Eller-Woywod; S Schmickler; J Inderfurth; P Hoffmann; C Ohlmeyer; B Kammering; D Pauleikhoff
Journal:  Ophthalmologe       Date:  2020-04       Impact factor: 1.059

3.  PERSEUS 24-month analysis: a prospective non-interventional study to assess the effectiveness of intravitreal aflibercept in routine clinical practice in Germany in patients with neovascular age-related macular degeneration.

Authors:  Nicole Eter; Zoran Hasanbasic; Georgios Keramas; Christine Rech; Helmut Sachs; Harald Schilling; Joachim Wachtlin; Peter Wiedemann; Carsten Framme
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2021-02-06       Impact factor: 3.117

Review 4.  [Adherence to anti-VEGF treatment-Considerations and practical recommendations].

Authors:  Albrecht Lommatzsch; Nicole Eter; Christoph Ehlken; Ines Lanzl; Hakan Kaymak; Alexander K Schuster; Focke Ziemssen
Journal:  Ophthalmologe       Date:  2020-12-03       Impact factor: 1.059

5.  Importance of Treatment Duration: Unmasking Barriers and Discovering the Reasons for Undertreatment of Anti-VEGF Agents in Neovascular Age-Related Macular Degeneration.

Authors:  Bianka Sobolewska; Muhammed Sabsabi; Focke Ziemssen
Journal:  Clin Ophthalmol       Date:  2021-10-27

6.  IMPACT study: Impact of adherence to anti-VEGF intravitreal injections for macular disease during COVID 19-related confinement in France.

Authors:  Victoire Hurand; Jean-Baptiste Ducloyer; Florian Baudin; Serge Aho; Michel Weber; Laurent Kodjikian; François Devin; Pierre-Henry Gabrielle; Catherine Creuzot-Garcher; Pascale Massin
Journal:  Acta Ophthalmol       Date:  2022-06-29       Impact factor: 3.988

7.  Association of treatment adherence with real-life VA outcomes in AMD, DME, and BRVO patients.

Authors:  Christoph Ehlken; Mandy Helms; Daniel Böhringer; Hansjürgen T Agostini; Andreas Stahl
Journal:  Clin Ophthalmol       Date:  2017-12-20

8.  Importance of continuous treatment with intravitreal aflibercept injections in patients with neovascular age-related macular degeneration-12-month post hoc analysis of the PERSEUS real-world evidence study.

Authors:  Joachim Wachtlin; Nicole Eter; Zoran Hasanbasic; Georgios Keramas; Christine Rech; Helmut Sachs; Harald Schilling; Peter Wiedemann; Carsten Framme
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2020-08-13       Impact factor: 3.117

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.